ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
AlloVir Inc

AlloVir Inc (ALVR)

0.7549
-0.0066
(-0.87%)
Closed March 29 04:00PM
0.7549
0.00
(0.00%)
After Hours: 06:11PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.7549
Bid
0.745
Ask
0.79
Volume
381,001
0.74 Day's Range 0.7885
0.6231 52 Week Range 6.12
Market Cap
Previous Close
0.7615
Open
0.74
Last Trade Time
Financial Volume
$ 288,312
VWAP
0.756723
Average Volume (3m)
1,301,928
Shares Outstanding
114,063,336
Dividend Yield
-
PE Ratio
-0.51
Earnings Per Share (EPS)
-1.48
Revenue
-
Net Profit
-168.71M

About AlloVir Inc

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting fi... AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
AlloVir Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALVR. The last closing price for AlloVir was $0.76. Over the last year, AlloVir shares have traded in a share price range of $ 0.6231 to $ 6.12.

AlloVir currently has 114,063,336 shares outstanding. The market capitalization of AlloVir is $86.69 million. AlloVir has a price to earnings ratio (PE ratio) of -0.51.

ALVR Latest News

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, March 14, 2024 NEW YORK, March 14, 2024 /PRNewswire/ --ย The Gross...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR PR Newswire NEW YORK, March 7, 2024 NEW YORK, March 7, 2024 /PRNewswire/...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, Feb. 22, 2024 NEW YORK, Feb. 22, 2024 /PRNewswire/ -- The Gross...

Form 144 - Report of proposed sale of securities

="/Images/box-unchecked.jpg" alt="Checkbox not checked">515502/21/2024N/A* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the...

Form 144 - Report of proposed sale of securities

="/Images/box-unchecked.jpg" alt="Checkbox not checked">309702/20/2024N/A* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the...

Form RW - Registration Withdrawal Request

AlloVir, Inc. 1100 Winter Street Waltham, MA 02451 February 15, 2024 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E...

Form 8-K - Current report

false 0001754068 0001754068 2024-02-09 2024-02-09     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT...

Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Feb. 9, 2024 NEW YORK, Feb. 9, 2024 /PRNewswire/...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00961.288071917350.74530.80.746260110.76031005CS
40.03494.847222222220.720.80.674870730.74797439CS
120.114917.9531250.640.80.623113019280.69377723CS
26-1.4551-65.84162895932.212.4850.623114159501.01365829CS
52-3.4451-82.02619047624.26.120.623110355911.73571324CS
156-20.8751-96.509939898321.6326.410.62316682295.22603473CS
260-22.0651-96.691936897522.8248.960.62316101838.0392913CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

ALVR Discussion

View Posts
Monksdream Monksdream 1 month ago
ALVR 1O Q 2/26
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 3 months ago
AlloVir shedding 95% of its staff after discontinuing T cell therapy trial
https://www.morningstar.com/news/marketwatch/202401041038/allovir-shedding-95-of-its-staff-after-discontinuing-t-cell-therapy-trial
๐Ÿ‘๏ธ0
starkd748 starkd748 3 months ago

26s
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
ALVR new 52 week low
๐Ÿ‘๏ธ0
starkd748 starkd748 3 months ago
Waiting to see if .20s come
๐Ÿ‘๏ธ0
KOmani KOmani 3 months ago
Gilead owns about 13 Million shares of the total 114 Million outstanding.

I think if they offered $1.50 they could buy the rest of the shares for basically the cash on hand less liabilities.

Is the value of the pipeline $0?

I doubt it, but worse case it is.

I don't know, but $0.75-0.80 seems decent even for a bounce just to $1

I am more saying why I would get in should there start to be buy in and support from bigger pockets.
๐Ÿ‘๏ธ0
redspinelpinktopaz redspinelpinktopaz 3 months ago
Agree. Not too bright addition.
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
ALVR new 52 week low
๐Ÿ‘๏ธ0
Lwrnc2052 Lwrnc2052 3 months ago
Tpet
๐Ÿ‘๏ธ0
jobynimble jobynimble 3 months ago
Exhibit 99.1 Press release: https://www.sec.gov/Archives/edgar/data/1754068/000119312523301777/d671953dex991.htm

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified
Company to prioritize capital preservation and review strategic options

AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023
Waltham, Mass โ€“ December 22, 2023 โ€“ AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV). The company will discontinue its three global Phase 3 posoleucel studies โ€“ for prevention of clinically significant infections or diseases by multiple viruses, treatment of virus-associated hemorrhagic cystitis (vHC), and treatment of adenovirus (AdV) โ€“ following allogeneic hematopoietic cell transplant (allo-HCT). The company made the determination following three pre-planned analyses by three independent Data Safety Monitoring Boards (DSMBs) each of which recommended stopping its respective trial for futility after a review of the data suggested that each study was unlikely to meet its primary endpoint. There were no observed safety concerns raised by any of the DSMBs.

AlloVir is in the process of notifying regulatory agencies and clinical trial investigators involved in these trials of the findings.
โ€œWhile we are disappointed by the unexpected outcome of these trials, we are encouraged by the apparent safety profile of posoleucel,โ€ said Diana Brainard, MD, Chief Executive Officer of AlloVir. โ€œIn light of the DSMB recommendations, we will discontinue the prevention, vHC and AdV Phase 3 trials. We will continue to analyze the data from these studies to understand any variables that may have impacted outcomes or any apparent subpopulation benefits. We thank the patients, investigators and staff who participated in the trials.โ€

Dr. Brainard continued, โ€œWe established pre-planned futility analyses across these three Phase 3 trials, as each assessed a potentially highly innovative treatment for patients suffering with severe and complex medical conditions lacking significant prior clinical development, and we also expected the trials would require substantial additional capital to bring them to completion. With these current results, we will immediately shift our focus to preserve our substantial remaining capital, review our pipeline, and assess strategic options.โ€

AlloVir will review strategic alternatives for the Company and its portfolio of virus-specific T cell therapies. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction. As of September 30, 2023, AlloVir had cash, cash equivalents and short-term investments of $213.3 million.

About AlloVirโ€™s Earlier Stage Virus-Specific T cell Pipeline

Adult Kidney Transplantation

AlloVir has earlier reported the results of its completed Phase 2 randomized, placebo-controlled trial evaluating posoleucel for the treatment of BKV infection in adult kidney transplant patients. After 24 weeks of treatment, 39% of patients receiving posoleucel experienced a =1-log viral load reduction, compared to 14% of patients receiving placebo.

Acute Respiratory Infection

The company has completed Part A of a randomized, placebo-controlled Phase 1b/2a trial with ALVR106 in 14 stem cell or solid organ transplant patients. ALVR106 is an investigational allogeneic, off-the-shelf, multi-virus-specific VST therapy candidate designed to target diseases caused by human metapneumovirus (hMPV), influenza, parainfluenza virus (PIV) and respiratory syncytial virus (RSV). Data has been accepted for presentation at a scientific conference in the first quarter of 2024.
Chronic Hepatitis B Infection

ALVR107 is an investigational allogeneic, off-the-shelf VST therapy designed to target hepatitis B virus (HBV)-infected cells and potentially cure patients with chronic HBV infection. Preclinical and IND-enabling studies support the advancement of ALVR107 into a clinical proof of concept study as a next step.

About AlloVir

AlloVir is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyโ€™s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVirโ€™s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. For more information, visit www.allovir.com or follow us on X or LinkedIn.
๐Ÿ‘๏ธ0
jobynimble jobynimble 3 months ago
8-K filing:https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312523301777/d671953d8k.htm

Item 7.01
Regulation FD Disclosure
On December 22, 2023, AlloVir, Inc. (โ€œAlloVirโ€) issued a press release titled โ€œAlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T-Cell Therapy.โ€ The press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed โ€œfiledโ€ for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the โ€œExchange Actโ€) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01
Other Events.
On December 22, 2023, AlloVir announced that it is discontinuing enrollment in its three ongoing Phase 3 Posoleucel studies for (i) prevention of clinically significant infections or diseases by multiple viruses, (ii) treatment of virus-associated hemorrhagic cystitis, and (iii) treatment of adenovirus, all following allogeneic hematopoietic cell transplant.

Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits

Exhibit No. Description
99.1 Press release dated December 22, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 3 months ago
They did say: "we are encouraged by the apparent safety profile of posoleucel".
Yes, water also has a great safety profile, but doesn't cure a damn thing except thirst.
NOT GOOD - NOT GOOD AT ALL.
👍️ 1
microcapbiotech microcapbiotech 3 months ago
NOT GOOD NEWS.
๐Ÿ‘๏ธ0
starkd748 starkd748 3 months ago
The chart never lies
๐Ÿ‘๏ธ0
Handbag Handbag 3 months ago
Damn, That was quick
๐Ÿ‘๏ธ0
starkd748 starkd748 3 months ago
I'm going to wait till next week
๐Ÿ‘๏ธ0
starkd748 starkd748 3 months ago
Wow I love the technicals analysis....I didn't read the PR or anything I just knew the chart was fugly ugly lol... Fundamentals don't mean squat ....I need to check to see if this is oversold look up the Fibonacci retracement and the stochastic rsi...
๐Ÿ‘๏ธ0
KOmani KOmani 3 months ago
Below $1 now.

Report said they have $213.3 million as of Sept 30

With 114 million shares outstanding, this seems cheap?

If this catches a bid, might see a bit of a pop.
๐Ÿ‘๏ธ0
starkd748 starkd748 4 months ago
Need this below 1.00 then I buy for a flip
๐Ÿ‘๏ธ0
jobynimble jobynimble 4 months ago
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
November 16 2023 - 07:00AM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.


View source version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/
๐Ÿ‘๏ธ0
starkd748 starkd748 5 months ago
I'm out come below 1s
💀 1 ☠️ 1 ⚰️ 1
starkd748 starkd748 5 months ago
No below 1s but my 1.30s look good
๐Ÿ‘๏ธ0
starkd748 starkd748 5 months ago
Tank below 1s
๐Ÿ‘๏ธ0
starkd748 starkd748 5 months ago
Her come 1.20s
๐Ÿ‘๏ธ0
starkd748 starkd748 5 months ago
The chart is still in free fall looking for a bottom
๐Ÿ‘๏ธ0
Handbag Handbag 5 months ago
No way. Will be a 25-30 Million market cap soon.
๐Ÿ‘๏ธ0
starkd748 starkd748 5 months ago
Will 1.20s hold
๐Ÿ‘๏ธ0
starkd748 starkd748 5 months ago
Yes tank more
💩 1 🤡 1
starkd748 starkd748 5 months ago
Come on below 1s please
👧 1 💩 1 🤡 1
starkd748 starkd748 5 months ago
Need more read below 1s would be a possible buy
💩 1 🤡 1 🤥 1
starkd748 starkd748 5 months ago
Need more
🤡 1
starkd748 starkd748 6 months ago
Need more tankage
💩 1 🤡 1
starkd748 starkd748 6 months ago
Tank baby tank below 1s
👧 1 💩 1 🤡 1
starkd748 starkd748 6 months ago
More red this week nearing a bottom easy flip once stochastic hit 0.... below 1.00 would be excellent
👧 1 🤡 1 🤥 1
starkd748 starkd748 6 months ago
Almost ready
👧 1 💩 1 🤡 1
starkd748 starkd748 6 months ago
Tank hard then I buy for a flip
👧 1 💩 1 🤡 1
microcapbiotech microcapbiotech 6 months ago
Bought more today @ $2.16
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 8 months ago
Bought more today again under $3
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 8 months ago
still on watch
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 8 months ago
Bought more today under $3.
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 8 months ago
I bought in at under $3. On 6-29 10% owner Gilead Sciences Inc acquired a total 2,930,870 shares an average price of $3.75.
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 8 months ago
Just started a position in ALVR.
๐Ÿ‘๏ธ0
learningcurve2020 learningcurve2020 10 months ago
Nobody? What about PL is he here?
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock